<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7114316/results/search/disease/results.xml">
  <result pre="molecules and natural compounds targeting the 3CL protease of feline" exact="infectious" post="peritonitis virus TheerawatanasirikulSirinaKuoChih Jungck476@nchu.edu.twb∗∗PhetcharatNanthawancLekcharoensukPorntippafvetptn@ku.ac.thcd∗[a], [b], [c], [d], ∗Corresponding author."/>
  <result pre="and natural compounds targeting the 3CL protease of feline infectious" exact="peritonitis" post="virus TheerawatanasirikulSirinaKuoChih Jungck476@nchu.edu.twb∗∗PhetcharatNanthawancLekcharoensukPorntippafvetptn@ku.ac.thcd∗[a], [b], [c], [d], ∗Corresponding author. Department"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="discovery of candidate compounds. To find small molecules with anti-feline" exact="infectious" post="peritonitis virus (FIPV) properties, we utilized a virtual screening"/>
  <result pre="of candidate compounds. To find small molecules with anti-feline infectious" exact="peritonitis" post="virus (FIPV) properties, we utilized a virtual screening technique"/>
  <result pre="virtual screening technique to identify the active site on the" exact="viral" post="protease for the binding of the available natural compounds."/>
  <result pre="on the Ro5 recommendation for further drug development. Keywords Feline" exact="infectious" post="peritonitis virus (FIPV) 3CL protease Natural compounds Antiviral activity"/>
  <result pre="the Ro5 recommendation for further drug development. Keywords Feline infectious" exact="peritonitis" post="virus (FIPV) 3CL protease Natural compounds Antiviral activity Virtual"/>
  <result pre="Natural compounds Antiviral activity Virtual screening Coronavirus 1 Introduction Feline" exact="infectious" post="peritonitis (FIP), caused by the virulent biotype of feline"/>
  <result pre="compounds Antiviral activity Virtual screening Coronavirus 1 Introduction Feline infectious" exact="peritonitis" post="(FIP), caused by the virulent biotype of feline coronavirus"/>
  <result pre="Alphacoronavirus in the family Coronaviridae, is a progressive and fatal" exact="disease" post="of cats. Feline infectious peritonitis virus (FIPV) is a"/>
  <result pre="Coronaviridae, is a progressive and fatal disease of cats. Feline" exact="infectious" post="peritonitis virus (FIPV) is a mutated form of the"/>
  <result pre="is a progressive and fatal disease of cats. Feline infectious" exact="peritonitis" post="virus (FIPV) is a mutated form of the parental"/>
  <result pre="et al., 2009; Pedersen, 2009, 2014a). FIP is a serious" exact="systemic" post="(pyo-) granulomatous disease that causes protein-rich effusions in the"/>
  <result pre="Pedersen, 2009, 2014a). FIP is a serious systemic (pyo-) granulomatous" exact="disease" post="that causes protein-rich effusions in the body cavities. This"/>
  <result pre="disease that causes protein-rich effusions in the body cavities. This" exact="disease" post="progresses severely within a week to few months, before"/>
  <result pre="polyproteins. The translation of ORF1a yields the polyprotein pp1a. At" exact="lower" post="frequencies, ribosomes initiate translation at the beginning of ORF1a"/>
  <result pre="et al., 2015) that plays a pivotal role in the" exact="viral" post="life cycle, including the processing of polyprotein and viral"/>
  <result pre="the viral life cycle, including the processing of polyprotein and" exact="viral" post="replication. The polyprotein pp1a and pp1ab are subsequently enzymatically"/>
  <result pre="to nsp16) that are mainly involved in proteolytic processing and" exact="viral" post="RNA synthesis, including the replication of the genome and"/>
  <result pre="antiviral activities against the 3CLpro of SARs-CoV and interfere with" exact="viral" post="replication (Lin et al., 2005; Ryu et al., 2010)."/>
  <result pre="library The crystal structure of 3CLpro was obtained from the" exact="Protein" post="Data Bank (PDB) (ID: 5EU8). This structure was processed"/>
  <result pre="tautomerization states of the binding site residues, and calculating the" exact="partial" post="charge using the program Chimera (UCSF, San Francisco, USA)."/>
  <result pre="pdb and mol2 files for subsequent molecular docking analysis. A" exact="total" post="of 8,338 structural files of natural compounds were retrieved"/>
  <result pre="the Km value. The initial rate up to 10% substrate" exact="consumption" post="was used to calculate the kinetic parameters using the"/>
  <result pre="feline kidney (CRFK) cell line (ATCC, CCL–94) was used for" exact="viral" post="propagation and titration. The cell lines were maintained in"/>
  <result pre="48 h. The cytopathic effect (CPE) was observed by an" exact="inverted" post="microscope (Olympus CKX41, Tokyo, Japan). The infected cells were"/>
  <result pre="cells were incubated at 37 °C for 2 h for" exact="viral" post="adsorption. Then, the infected-CRFK cells were incubated for 24"/>
  <result pre="CRFK cells were incubated with the candidate compounds prior to" exact="viral" post="inoculation. The seeded CRFK cells were first incubated overnight,"/>
  <result pre="for 20 min and then washed with PBST buffer. The" exact="primary" post="antibody for detection of FIPV, a mouse monoclonal antibody"/>
  <result pre="washed using PBST, following which they were incubated with the" exact="secondary" post="antibody, a goat anti-mouse IgG-HRP antibody (dilution 1:400, Kirkegaard"/>
  <result pre="substrate (DAKO, Santa Clara, USA) and observed under a phase-contrast" exact="inverted" post="microscope (Olympus CKX41, Tokyo, Japan). 2.9 Image analysis The"/>
  <result pre="compound inhibited 50% of the infected cells (EC50) in the" exact="absence of" post="drug was determined. The selectivity index (SI) was calculated"/>
  <result pre="selectivity index (SI) was calculated as SI = CC50/EC50. 2.10" exact="Viral" post="quantification using real-time qPCR The RNA was extracted from"/>
  <result pre="qPCR The RNA was extracted from supernatants of each sample." exact="Viral" post="RNAs were extracted using the Trizol Total RNA extraction"/>
  <result pre="of each sample. Viral RNAs were extracted using the Trizol" exact="Total" post="RNA extraction kit (Invitrogen™, Carlsbad, USA) according to the"/>
  <result pre="al., 2009). The sequences of primers specific to the FCoV" exact="viral" post="genome were: 5′-GGCAACCCGATGTTTAAAACTGG-3’ (upstream; nucleotides 1 to 23) and"/>
  <result pre="software CFX Maestro™ (Bio-Rad, Hercules, USA). The absolute quantities of" exact="viral" post="copy numbers were calculated for each treatment and control."/>
  <result pre="activities of the selected candidate compounds were presented as percent" exact="viral" post="reduction by each compound compared to the control, and"/>
  <result pre="three docking tools for the FIPV 3CLpro validation dataset. 3.2" exact="Protein" post="purification and inhibition of FIPV 3CLpro Recombinant his-tagged FIPV"/>
  <result pre="value was 0.71 ± 0.04 s−1 (Fig. 2B). Fig. 2" exact="Protein" post="purification and kinetic parameters of FIPV 3CLpro. (A) SDS-PAGE"/>
  <result pre="of the intact FIPV 3CLpro and the fusion tag at" exact="lower" post="molecular mass appear on SDS-PAGE. Lane 6 shows the"/>
  <result pre="tested using the inhibition assay against FIPV 3CLpro. During the" exact="primary" post="screening, seven compounds showed more than 50% inhibition of"/>
  <result pre="3.4 Antiviral activities of the natural compounds We evaluated the" exact="viral infection" post="based on differential expression of the FIPV antigens within"/>
  <result pre="Antiviral activities of the natural compounds We evaluated the viral" exact="infection" post="based on differential expression of the FIPV antigens within"/>
  <result pre="in CRFK cells during the post-viral entry step of FIPV" exact="infection" post="when FIPV 3CLpro was also expressed by the viral"/>
  <result pre="FIPV infection when FIPV 3CLpro was also expressed by the" exact="viral" post="gene. The results indicated that three compounds had the"/>
  <result pre="NSC345647, NSC87511, and NSC343256 could completely protect the cells from" exact="virus infection" post="at concentrations of 20–50 μM. However, the remaining compounds"/>
  <result pre="NSC87511, and NSC343256 could completely protect the cells from virus" exact="infection" post="at concentrations of 20–50 μM. However, the remaining compounds"/>
  <result pre="20–50 μM. However, the remaining compounds could not inhibit FIPV" exact="infection" post="in any of these conditions, despite having good IC50"/>
  <result pre="(Table 1). The qPCR results showed that the percentage of" exact="viral" post="reduction by the selected compounds in all the three"/>
  <result pre="a positive drug control. Three controls for each compound (FIPV" exact="infection" post="without the compound treatment, FIPV ± Tx; no infection"/>
  <result pre="(FIPV infection without the compound treatment, FIPV ± Tx; no" exact="infection" post="with compound, -FIPV/+Tx; no infection without compound, -FIPV/-Tx) are"/>
  <result pre="treatment, FIPV ± Tx; no infection with compound, -FIPV/+Tx; no" exact="infection" post="without compound, -FIPV/-Tx) are presented on the upper panel."/>
  <result pre="-FIPV/+Tx; no infection without compound, -FIPV/-Tx) are presented on the" exact="upper" post="panel. The three-antiviral cell-based conditions; pre-viral entry, post-viral entry,"/>
  <result pre="the text. Fig. 4 Real-time qPCR (A–D) demonstrating percent of" exact="viral" post="reduction in the FIPV-infected CRFK cells after being treated"/>
  <result pre="prophylaxis activities as described in the text. The reductions of" exact="viral" post="copy numbers were related to that of FIPV-infected CRFK"/>
  <result pre="were related to that of FIPV-infected CRFK cells in the" exact="absence of" post="any compounds. 3.5 Protein-ligand interaction The protease-inhibition and antiviral"/>
  <result pre="NSC345647 (upper panel A, alkyl/π-alkyl: His41, Cys144, Pro188; π-donor: Glu165;" exact="lower" post="panel A, hydrophobic interaction: Thr47, Phe139, Ala141, His163; hydrogen"/>
  <result pre="hydrogen bond: Ile140, Gly142, Cys144, Glu165); 2) compound NSC87511 (B" exact="upper" post="panel, alkyl/π-alkyl: His163, Leu164, Pro188; π-sigma: His41; lower panel"/>
  <result pre="NSC87511 (B upper panel, alkyl/π-alkyl: His163, Leu164, Pro188; π-sigma: His41;" exact="lower" post="panel B, hydrophobic interactions: Cys144, Asp186, Gln187; hydrogen bond:"/>
  <result pre="(upper panel C, Alkyl/π-alkyl:Cys144, Pro188; π-π stacking: His41; hydrogen bond:THR47;" exact="lower" post="panel C, hydrophobic interactions: Asn25, Glu118, His163, Leu164, Asp186,"/>
  <result pre="cancers was simulated, and chaetochromin B was observed to be" exact="stable" post="in the binding pocket, making it a promising antiviral"/>
  <result pre="drug (Omer and Singh, 2017). In our study, the three" exact="viral infection" post="assays showed that chaetochromin could inhibit FIPV infection, with"/>
  <result pre="(Omer and Singh, 2017). In our study, the three viral" exact="infection" post="assays showed that chaetochromin could inhibit FIPV infection, with"/>
  <result pre="is produced by the lichens. The polyketides and their unique" exact="secondary" post="metabolites containing aromatic rings are commonly found in stictic"/>
  <result pre="could react with the Cys141 within the cysteine triad of" exact="tumor" post="suppressor protein p53, to reduce its reactivation in human"/>
  <result pre="extracted from lichens using acetone could inhibit the replication of" exact="hepatitis" post="C virus (Vu et al., 2015). In addition, the"/>
  <result pre="lactam similar to hitachimycin, showed antiviral effects against influenza virus" exact="type A" post="(Victoria strain) in MDCK cell culture, with IC50 ="/>
  <result pre="from isolated is known to interfere with the synthesis of" exact="viral" post="mRNA and viral replication, and is primarily indicated for"/>
  <result pre="known to interfere with the synthesis of viral mRNA and" exact="viral" post="replication, and is primarily indicated for hepatitis C virus"/>
  <result pre="viral mRNA and viral replication, and is primarily indicated for" exact="hepatitis" post="C virus (Dixit and Perelson, 2006). The activity of"/>
  <result pre="observed that lopinavir effectively inhibited FIPV during the stage of" exact="viral" post="entry (EC50 = 5.38–31.70 μM). It is possible that"/>
  <result pre="of lopinavir might involve the blocking of furin-mediated cleavage during" exact="viral" post="entry. Therefore, the mechanism of action of lopinavir on"/>
  <result pre="CID5372747 also inhibited protease activity, but could not control FIPV" exact="infection" post="under all the tested conditions. It is possible that"/>
  <result pre="influenced by unknown factors within the cell-culture conditions, resulting in" exact="lower" post="activity. The three compounds (NSC345647, NSC87511, and NSC343256) with"/>
  <result pre="than the broad spectrum antiviral drug, ribavirin, and the known" exact="viral" post="protease inhibitor, lopinavir, were less effective when their activities"/>
  <result pre="3CLpro, which is responsible for poly-protein processing in CoV during" exact="viral" post="replication. We identified three best candidate compounds that possessed"/>
  <result pre="N-oxide derivatives are inhibitory to the human SARS and feline" exact="infectious" post="peritonitis coronavirus in cell cultureJ. Antimicrob. Chemother.57200647248116387746 BerryM.FieldingB.C.GamieldienJ.Potential broad"/>
  <result pre="derivatives are inhibitory to the human SARS and feline infectious" exact="peritonitis" post="coronavirus in cell cultureJ. Antimicrob. Chemother.57200647248116387746 BerryM.FieldingB.C.GamieldienJ.Potential broad spectrum"/>
  <result pre="ribavirin: lethal mutagenesis of RNA virus genomes mediated by the" exact="viral" post="RNA-dependent RNA polymeraseCurr. Opin. Infect. Dis.14200175776411964896 ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.L.TseM.W.QueT.L.PeirisJ.S.M.SungJ.WongV.C.W.YuenK.Y.Treatment of severe"/>
  <result pre="viral RNA-dependent RNA polymeraseCurr. Opin. Infect. Dis.14200175776411964896 ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.L.TseM.W.QueT.L.PeirisJ.S.M.SungJ.WongV.C.W.YuenK.Y.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
  <result pre="RNA-dependent RNA polymeraseCurr. Opin. Infect. Dis.14200175776411964896 ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.L.TseM.W.QueT.L.PeirisJ.S.M.SungJ.WongV.C.W.YuenK.Y.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
  <result pre="RNA polymeraseCurr. Opin. Infect. Dis.14200175776411964896 ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.L.TseM.W.QueT.L.PeirisJ.S.M.SungJ.WongV.C.W.YuenK.Y.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
  <result pre="metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against" exact="hepatitis" post="C virusCell. Mol. Life Sci.63200683284216501888 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-α2b"/>
  <result pre="large multi-domain proteinAntivir. Res.1492018587429128390 LinC.-N.ChangR.-Y.SuB.-L.ChuehL.-L.Full genome analysis of a novel" exact="type II" post="feline coronavirus NTU156Virus Genes46201331632223239278 LinC.-W.TsaiF.-J.TsaiC.-H.LaiC.-C.WanL.HoT.-Y.HsiehC.-C.ChaoP.-D.L.Anti-SARS coronavirus 3C-like protease effects"/>
  <result pre="Discov. Today Technol.1200433734124981612 Lohézic-Le DévéhatF.TomasiS.ElixJ.A.RouaudI.UriacP.RennesD.Lohezic-Le DevehatF.TomasiS.ElixJ.A.BernardA.RouaudI.UriacP.BoustieJ.Stictic acid derivatives from the" exact="lichen" post="Usnea articulata and their antioxidant activitiesJ. Nat. Prod.7020071218122017629329 ManasateinkijW.NilkumhangP.JaroensongT.NoosudJ.LekcharoensukC.LekcharoensukP.Occurrence"/>
  <result pre="antioxidant activitiesJ. Nat. Prod.7020071218122017629329 ManasateinkijW.NilkumhangP.JaroensongT.NoosudJ.LekcharoensukC.LekcharoensukP.Occurrence of feline coronavirus and feline" exact="infectious" post="peritonitis virus in ThailandKasetsart J./Nat. Sci.432009720726 MiyanagaA.HayakawaY.NumakuraM.HashimotoJ.TeruyaK.HiranoT.Shin-YaK.KudoF.EguchiT.Identification of the"/>
  <result pre="activitiesJ. Nat. Prod.7020071218122017629329 ManasateinkijW.NilkumhangP.JaroensongT.NoosudJ.LekcharoensukC.LekcharoensukP.Occurrence of feline coronavirus and feline infectious" exact="peritonitis" post="virus in ThailandKasetsart J./Nat. Sci.432009720726 MiyanagaA.HayakawaY.NumakuraM.HashimotoJ.TeruyaK.HiranoT.Shin-YaK.KudoF.EguchiT.Identification of the fluvirucin"/>
  <result pre="Struct. Dyn.3520171547155827484103 OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221"/>
  <result pre="Dyn.3520171547155827484103 OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 PapadopoulouP.TzakouO.VagiasC.KefalasP.RoussisV.β-Orcinol"/>
  <result pre="a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 PapadopoulouP.TzakouO.VagiasC.KefalasP.RoussisV.β-Orcinol metabolites from the" exact="lichen" post="Hypotrachyna revolutaMolecules2007 PedersenN.C.An update on feline infectious peritonitis: virology"/>
  <result pre="metabolites from the lichen Hypotrachyna revolutaMolecules2007 PedersenN.C.An update on feline" exact="infectious" post="peritonitis: virology and immunopathogenesisVet. J.201201412313224837550 PedersenN.C.An update on feline"/>
  <result pre="infectious peritonitis: virology and immunopathogenesisVet. J.201201412313224837550 PedersenN.C.An update on feline" exact="infectious" post="peritonitis: diagnostics and therapeuticsVet. J.201201413314124857253 PedersenN.C.A review of feline"/>
  <result pre="infectious peritonitis: diagnostics and therapeuticsVet. J.201201413314124857253 PedersenN.C.A review of feline" exact="infectious" post="peritonitis virus infection: 1963-2008J. Feline Med. Surg.11200922525819254859 RyuY.B.JeongH.J.KimJ.H.KimY.M.ParkJ.-Y.KimD.NaguyenT.T.H.ParkS.-J.ChangJ.S.ParkK.H.RhoM.-C.LeeW.S.Biflavonoids from"/>
  <result pre="peritonitis: diagnostics and therapeuticsVet. J.201201413314124857253 PedersenN.C.A review of feline infectious" exact="peritonitis" post="virus infection: 1963-2008J. Feline Med. Surg.11200922525819254859 RyuY.B.JeongH.J.KimJ.H.KimY.M.ParkJ.-Y.KimD.NaguyenT.T.H.ParkS.-J.ChangJ.S.ParkK.H.RhoM.-C.LeeW.S.Biflavonoids from Torreya"/>
  <result pre="Chem. Lett13200371371712639565 St JohnS.E.TherkelsenM.D.NyalapatlaP.R.OsswaldH.L.GhoshA.K.MesecarA.D.X-ray structure and inhibition of the feline" exact="infectious" post="peritonitis virus 3C-like protease: structural implications for drug designBioorg."/>
  <result pre="Lett13200371371712639565 St JohnS.E.TherkelsenM.D.NyalapatlaP.R.OsswaldH.L.GhoshA.K.MesecarA.D.X-ray structure and inhibition of the feline infectious" exact="peritonitis" post="virus 3C-like protease: structural implications for drug designBioorg. Med."/>
  <result pre="controlled-release drug delivery: lessons from microbesFront. Pharmacol.92019118 VuT.H.LamerA.C. LeLalliC.SamsonJ.B.M.DévéhatF.L.Le SeyecJ.LeDepsides:" exact="lichen" post="metabolites active against hepatitis C virusPLoS One102015114 WangF.ChenC.LiuX.YangK.XuX.YangH.Crystal structure"/>
  <result pre="from microbesFront. Pharmacol.92019118 VuT.H.LamerA.C. LeLalliC.SamsonJ.B.M.DévéhatF.L.Le SeyecJ.LeDepsides: lichen metabolites active against" exact="hepatitis" post="C virusPLoS One102015114 WangF.ChenC.LiuX.YangK.XuX.YangH.Crystal structure of feline infectious peritonitis"/>
  <result pre="active against hepatitis C virusPLoS One102015114 WangF.ChenC.LiuX.YangK.XuX.YangH.Crystal structure of feline" exact="infectious" post="peritonitis virus main protease in complex with synergetic dual"/>
  <result pre="against hepatitis C virusPLoS One102015114 WangF.ChenC.LiuX.YangK.XuX.YangH.Crystal structure of feline infectious" exact="peritonitis" post="virus main protease in complex with synergetic dual inhibitorsJ."/>
  <result pre="isolated from lichens: a systematic reviewMolecules192014144961452725221871 WuC.-Y.JanJ.-T.MaS.KuoC.-J.JuanH.-F.ChengY.-S.E.HsuH.-H.HuangH.-C.WuD.BrikA.LiangF.-S.LiuR.-S.FangJ.-M.ChenS.-T.LiangP.-H.WongC.-H.Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirusProc. Natl. Acad. Sci.1012004100121001715226499 ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery"/>
  <result pre="from lichens: a systematic reviewMolecules192014144961452725221871 WuC.-Y.JanJ.-T.MaS.KuoC.-J.JuanH.-F.ChengY.-S.E.HsuH.-H.HuangH.-C.WuD.BrikA.LiangF.-S.LiuR.-S.FangJ.-M.ChenS.-T.LiangP.-H.WongC.-H.Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirusProc. Natl. Acad. Sci.1012004100121001715226499 ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and"/>
  <result pre="lichens: a systematic reviewMolecules192014144961452725221871 WuC.-Y.JanJ.-T.MaS.KuoC.-J.JuanH.-F.ChengY.-S.E.HsuH.-H.HuangH.-C.WuD.BrikA.LiangF.-S.LiuR.-S.FangJ.-M.ChenS.-T.LiangP.-H.WongC.-H.Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirusProc. Natl. Acad. Sci.1012004100121001715226499 ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic"/>
 </snippets>
</snippetsTree>
